Natesan Chidambaram, Subramaniyam Sethupathy, Nadanam Saravanan, Toshiya Toda, Mari Mori, Yukio Yamori, Arun Kumar Garg and Arun Chockalingam
Forty subjects identified as dyslipidemic were assigned randomly to either soy powder (Soy) or red bean powder (Placebo). The soy group received daily a sachet of 18.1 g soy power containing 85 K cal and the placebo group received daily placebo sachet (23.1 g) of red bean powder containing 85.5 K cal in addition to the usual diet for four weeks. Intake of soy/placebo powder was assessed by measurement of 24-hour urinary isoflavone excretions at baseline and at the end of the intervention period. Relative to placebo, soy powder has significant effect over some Cardiovascular Disease (CVD) markers and Metabolic Syndrome (MetS) indices including abdominal circumference, triglycerides, HbA1c and insulin. These data support that the dietary consumption of soy has the property to reduce risk factors for CVD and MetS.
PDFShare this article
Journal of Hypertension: Open Access received 614 citations as per Google Scholar report